Tespa1在慢性鼻窦炎伴鼻息肉中的表达及作用研究

doi:10.6040/j.issn.1673-3770.0.2024.108

摘要/Abstract

摘要： 目的检测胸腺细胞表达的阳性选择相关蛋白1(thymocyte expressed, positive selection associated 1, Tespa1)在鼻息肉及鼻腔黏膜中的表达及表达差异,并探讨Tespa1在CRSwNP中的作用及其与肥大细胞的关系。方法研究纳入慢性鼻窦炎伴鼻息肉(chronic rhinosinusitis with Nasal Polyps, CRSwNP)患者29例、慢性鼻窦炎不伴鼻息肉(chronic rhinosinusitis without nasal polyps, CRSsNP)患者20例、对照组患者18例。应用实时定量聚合酶链反应(quantitative real-time PCR, qPCR)、免疫组织化学法(immunohistochemistry, IHC)、酶联免疫吸附试验(enzyme-linked immunosorbent assay, ELISA)、和苏木精-伊红(hematoxylin-eosin staining, H&E)染色,检测鼻腔黏膜及鼻息肉中Tespa1表达及分布,并分析了其与肥大细胞、IgE、IL-4及IL-13之间的相关性。结果 qPCR结果显示,CRSwNP中Tespa1 mRNA表达水平较对照组及CRSsNP组均显著降低(Z=2.42,P=0.046;Z=-3.38,P=0.002)。IHC结果显示,与对照组相比,Tespa1在鼻息肉的上皮和间质低表达,胰蛋白酶阳性的肥大细胞在鼻息肉中表达加(t=10.14,P<0.001)。鼻息肉中Tespa1 阳性细胞数与胰蛋白酶阳性肥大细胞数呈负相关(r=-0.710,P=0.006)。ELISA结果显示,组织中Tespa1水平远高于其在血清中的水平, 组织Tespa1水平与IgE、IL-4、IL-13水平呈负相关(r=-0.682,P=0.002;r=-0.691,P=0.002;r=-0.539,P=0.021)。结论 Tespa1在CRSwNP患者鼻息肉组织中低表达,与IgE、IL-4及IL-13表达水平负相关,并可能通过肥大细胞发挥作用。本研究为理解CRSwNP的病理机制提供了新的视角,并可能为未来的诊断和治疗提供新的分子靶标。

关键词: 慢性鼻窦炎伴鼻息肉, 胸腺细胞表达的阳性选择相关蛋白1, 肥大细胞

Abstract: Objective To determine the expression and expression differences of thymocyte-expressed, positive selection associated 1(Tespa1)in nasal polyps and nasal mucosa and to investigate the role of Tespa1 in CRSwNP and its relationship with mast cells. Methods Twenty-nine patients with chronic rhinosinusitis with nasal polyps(CRSwNP)and 20 patients with chronic rhinosinusitis without nasal polyps(CRSsNP)were included in the study, 18 cases of controls. Quantitative real-time PCR(qPCR), immunohistochemistry(IHC), enzyme-linked immunosorbent assay(ELISA), and hematoxylin-eosin(H&E)staining were used to detect the expression and distribution of Tespa1 in nasal mucosa and nasal polyps, and its correlation with mast cells, IgE, IL-4, and IL-13 was analyzed. Results The qPCR results showed that the expression level of Tespa1 mRNA in CRSwNP was significantly lower than that in both control and CRSsNP groups(Z=2.42, P=0.046; Z=-3.38, P=0.002). The IHC results showed that Tespa1 was lowly expressed in the epithelium and mesenchyme of nasal polyps compared with the control group, and the expression of tryptase-positive mast cells was upregulated in nasal polyps(t=10.14, P<0.001). The number of Tespa1-positive cells in nasal polyps was negatively correlated with the number of trypsin-positive mast cells(r=-0.710, P=0.006).The ELISA results showed that the tissue Tespa1 level was much higher than its level in serum, and the tissue Tespa1 level was negatively correlated with the levels of IgE, IL-4, and IL-13(r=-0.682, P=0.002; r=-0.682, P=0.002; r=-0.691, P=0.002; r=-0.539, P=0.021). Conclusions Tespa1 is low expressed in nasal polyp tissues of CRSwNP patients, negatively correlated with the expression levels of IgE, IL-4 and IL-13, and may act through mast cells. This study provides a new perspective for understanding the pathomechanism of CRSwNP and may provide new molecular targets for future diagnosis and treatment.

Key words: Chronic rhinosinusitis with nasal polyps, Thymocyte expressed, positive selection associated 1, Mast cell

中图分类号:

R765.4

张广玲,陈兴雪,武天义,孙占伟,王卫卫,李世超,王广科. Tespa1在慢性鼻窦炎伴鼻息肉中的表达及作用研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 35-42.

ZHANG Guangling, CHEN Xingxue, WU Tianyi, SUN Zhanwei, WANG Weiwei, LI Shichao,WANG Guangke. The expression and function of Tespa1 in chronic rhinosinusitis with nasal polyps[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 35-42.

参考文献

[1] Kim DH, Han JS, Kim GJ, et al. Clinical predictors of polyps recurring in patients with chronic rhinosinusitis and nasal polyps: a systematic review and meta-analysis[J]. Rhinology, 2023, 61(6): 482-497. doi:10.4193/Rhin23.136
[2] Wahid NW, Smith R, Clark A, et al. The socioeconomic cost of chronic rhinosinusitis study[J]. Rhinology, 2020, 58(2): 112-125. doi:10.4193/Rhin19.424
[3] Hwee J, Lee L, Small M, et al. The chronic rhinosinusitis with nasal polyp patient journey in the United States and Europe[J]. Allergy Asthma Clin Immunol, 2024, 20(1): 17. doi:10.1186/s13223-024-00879-7
[4] 姚爽, 娄鸿飞. 慢性鼻窦炎的内在型研究进展及精准医疗[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 20-29, 49. doi:10.6040/j.issn.1673-3770.0.2021.561 YAO Shuang, LOU Hongfei. Advances in endotypes and precision medicine in chronic rhinosinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 20-29, 49. doi:10.6040/j.issn.1673-3770.0.2021.561
[5] Dwyer DF, Ordovas-Montanes J, Allon SJ, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation[J]. Sci Immunol, 2021, 6(56): eabb7221. doi:10.1126/sciimmunol.abb7221
[6] Wang D, Zheng MZ, Lei L, et al. Tespa1 is involved in late thymocyte development through the regulation of TCR-mediated signaling[J]. Nat Immunol, 2012, 13(6): 560-568. doi:10.1038/ni.2301
[7] Liang JJ, Lyu J, Zhao M, et al. Tespa1 regulates T cell receptor-induced calcium signals by recruiting inositol 1, 4, 5-trisphosphate receptors[J]. Nat Commun, 2017, 8: 15732. doi:10.1038/ncomms15732
[8] Wang D, Zheng MZ, Qiu YJ, et al. Tespa1 negatively regulates FcεRI-mediated signaling and the mast cell-mediated allergic response[J]. J Exp Med, 2014, 211(13): 2635-2649. doi:10.1084/jem.20140470
[9] Yang RH, Wang GL, Li LY, et al. Tespa1 plays a role in the modulation of airway hyperreactivity through the IL-4/STAT6 pathway[J]. J Transl Med, 2020, 18(1): 444. doi:10.1186/s12967-020-02621-4
[10] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001 Subspecialty Group of Rhinology, Editorial Board of Chinese Jounal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, ChineseMedical Association. Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis(2018)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001
[11] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl S29): 1-464. doi:10.4193/Rhin20.600
[12] Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese[J]. J Allergy Clin Immunol, 2009, 124(3): 478-484, 484.1, 484.2. doi:10.1016/j.jaci.2009.05.017
[13] Dar SA, Rai G, Ansari MA, et al. FcR1α gene polymorphism shows association with high IgE and anti-FcR1α in Chronic Rhinosinusitis with Nasal Polyposis[J]. J Cell Biochem, 2018, 119(5): 4142-4149. doi:10.1002/jcb.26619
[14] Scheerens H, Smith A, Li O, et al. Elevated IgE M1 prime transcripts in nasal tissues in patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2019, 143(2): 805-807. doi:10.1016/j.jaci.2018.10.011
[15] Baba S, Kondo K, Suzukawa M, et al. Distribution, subtype population, and IgE positivity of mast cells in chronic rhinosinusitis with nasal polyps[J]. Ann Allergy Asthma Immunol, 2017, 119(2): 120-128. doi:10.1016/j.anai.2017.05.019
[16] Zhai GT, Li JX, Zhang XH, et al. Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps[J]. Laryngoscope, 2019, 129(3): 110-117. doi:10.1002/lary.27658
[17] Gion Y, Okano M, Koyama T, et al. Clinical significance of cytoplasmic IgE-positive mast cells in eosinophilic chronic rhinosinusitis[J]. Int J Mol Sci, 2020, 21(5): 1843. doi:10.3390/ijms21051843
[18] Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells[J]. Nature, 2018, 560(7720): 649-654. doi:10.1038/s41586-018-0449-8
[19] Yao YL, Huang W, Li XY, et al. Tespa1 deficiency dampens Thymus-dependent B-cell activation and attenuates collagen-induced arthritis in mice[J]. Front Immunol, 2018, 9: 965. doi:10.3389/fimmu.2018.00965
[20] Gelardi M, Giancaspro R, Duda L, et al. Eosinophil-mast cell pattern of intraepithelial infiltration as a marker of severity in CRSwNP[J]. Sci Rep, 2023, 13(1): 12101. doi:10.1038/s41598-023-39149-8
[21] Berlin F, Mogren S, Tutzauer J, et al. Mast cell proteases tryptase and chymase induce migratory and morphological alterations in bronchial epithelial cells[J]. Int J Mol Sci, 2021, 22(10): 5250. doi:10.3390/ijms22105250
[22] Rujitharanawong C, Yoodee S, Sueksakit K, et al. Systematic comparisons of various markers for mast cell activation in RBL-2H3 cells[J]. Cell Tissue Res, 2022, 390(3): 413-428. doi:10.1007/s00441-022-03687-w
[23] Takabayashi T, Kato A, Peters AT, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2012, 130(2): 410-420, 5. doi:10.1016/j.jaci.2012.02.046
[24] Gangwar RS, Pahima H, Puzzovio PG, et al. Update on eosinophil interaction with mast cells: the allergic effector unit[J]. Methods Mol Biol, 2021, 2241: 221-242. doi:10.1007/978-1-0716-1095-4_18
[25] Zhang N, Holtappels G, Gevaert P, et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB[J]. Allergy, 2011, 66(1): 141-148. doi:10.1111/j.1398-9995.2010.02448.x
[26] Asghari M, Izadpanahi S, Esfahani MH. Comparison of blood and tissue eosinophil count and blood IgE in patients with chronic sinusitis and nasal polyps[J]. J Immunol Res, 2021, 2021: 6680676. doi:10.1155/2021/6680676
[27] De Schryver E, Devuyst L, Derycke L, et al. Local immunoglobulin e in the nasal mucosa: clinical implications[J]. Allergy Asthma Immunol Res, 2015, 7(4): 321-331. doi:10.4168/aair.2015.7.4.321
[28] Shen Y, Zhang N, Yang YC, et al. Local immunoglobulin E in nasal polyps: role and modulation[J]. Front Immunol, 2022, 13: 961503. doi:10.3389/fimmu.2022.961503
[29] Bachert C, Maurer M, Palomares O, et al. What is the contribution of IgE to nasal polyposis?[J]. J Allergy Clin Immunol, 2021, 147(6): 1997-2008. doi:10.1016/j.jaci.2021.03.016
[30] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650. doi:10.1016/S0140-6736(19)31881-1

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed